A recent review highlights the promising effects of cannabinoids, a compound in cannabis, in managing persistent nerve pain. According to the research, cannabinoids may offer substantial pain relief with few or no side effects, suggesting a valuable alternative to conventional pain medications for patients dealing with persistent nerve pain.
Published in the Cureus journal, the review underscores the positive impact of cannabinoids on pain control, noting their benefits as a more natural option compared to synthetic drugs. This could make cannabinoids an attractive option for people seeking alternatives to traditional medications.
The research team, which sifted through numerous studies, narrowed their focus to five randomized, placebo-controlled trials conducted from 2000 to 2024. Their findings show that patients receiving cannabinoid treatment reported significantly higher pain relief than those given a placebo.
According to the study, cannabinoids led to pain relief in about 33% of participants, compared to just 15% in the placebo group, as measured by an analogous analog scale. For individuals experiencing sharp, intense pain, using CBD in a topical form provided even more relief, based on a neural pain scale. Importantly, very few side effects were reported, underscoring cannabinoids’ potential advantages in pain treatment.
According to the study, for those suffering from neuropathic pain—a type of pain caused by nerve damage often related to HIV/AIDS, diabetes, multiple sclerosis, shingles, and sometimes as a side effect of specific medications or radiation—finding effective treatments is complex. Such conditions often require specialized care and intensive medication regimens. In this context, cannabinoids may represent a breakthrough in pain management, offering a potentially more accessible and natural alternative for long-term relief.
The researchers acknowledge that more data is needed to understand the long-term side effects and potential interactions of cannabinoids, particularly due to varying legal restrictions and societal attitudes worldwide. Despite these challenges, they point out that cannabinoids may offer a new approach to chronic pain treatment, standing out as a natural remedy with minimal adverse effects.
The study also calls for further clinical trials to determine the most effective formulations and dosages of marijuana-derived medications for managing chronic pain.
As medical cannabis continues to gain legal acceptance in various states, chronic pain is among the top reasons for its medical use. Reports from both healthcare providers and patients suggest that marijuana can be a powerful alternative for pain management, reinforcing the case for it to be more widely considered in pain treatment strategies.
Companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) that believe in the therapeutic potential of marijuana and its compounds will be pleased that many recent studies, such as this review, are confirming the medicinal attributes of marijuana.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
